Aquestive Therapeutics IncNASDAQ:AQST
- LAST PRICE3.5550
- TODAY'S CHANGE (%)-0.1800 (-4.8193%)
- Bid / Lots3.5500/ 30
- Ask / Lots3.5600/ 11
- Open / Previous Close3.5900 / 3.7350
- Day Range
- 52 Week Range
- Volume637,544
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AQST |
|---|---|---|
| 09:32 ET | 54282 | 3.6 |
| 09:34 ET | 9590 | 3.6011 |
| 09:36 ET | 14581 | 3.62 |
| 09:38 ET | 23463 | 3.62 |
| 09:39 ET | 6407 | 3.63 |
| 09:41 ET | 11450 | 3.5702 |
| 09:43 ET | 5423 | 3.6 |
| 09:45 ET | 10522 | 3.6 |
| 09:48 ET | 10666 | 3.58 |
| 09:50 ET | 6469 | 3.585 |
| 09:52 ET | 6777 | 3.61 |
| 09:54 ET | 15661 | 3.645 |
| 09:56 ET | 3171 | 3.64 |
| 09:57 ET | 20597 | 3.65 |
| 09:59 ET | 3638 | 3.6123 |
| 10:01 ET | 2720 | 3.616 |
| 10:03 ET | 9526 | 3.615 |
| 10:06 ET | 2168 | 3.6191 |
| 10:08 ET | 39755 | 3.61 |
| 10:10 ET | 300 | 3.605 |
| 10:12 ET | 3593 | 3.61 |
| 10:14 ET | 3820 | 3.61 |
| 10:15 ET | 101 | 3.6149 |
| 10:17 ET | 3150 | 3.6168 |
| 10:19 ET | 48087 | 3.5839 |
| 10:21 ET | 7514 | 3.575 |
| 10:24 ET | 2220 | 3.56 |
| 10:26 ET | 19191 | 3.565 |
| 10:28 ET | 16793 | 3.565 |
| 10:30 ET | 12998 | 3.555 |
| 10:32 ET | 72657 | 3.555 |
| 10:33 ET | 6260 | 3.555 |
| 10:35 ET | 28484 | 3.565 |
| 10:37 ET | 7800 | 3.565 |
| 10:39 ET | 1581 | 3.57 |
| 10:42 ET | 15608 | 3.585 |
| 10:44 ET | 6906 | 3.575 |
| 10:46 ET | 9926 | 3.575 |
| 10:48 ET | 15800 | 3.56 |
| 10:50 ET | 6287 | 3.565 |
| 10:51 ET | 1626 | 3.56 |
| 10:53 ET | 11801 | 3.555 |
Today
Yesterday
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant(TM) (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm(TM) (epinephrine) Sublingual Film, from 7:00AM ET on Monday Apr 29, 2024 by Dow Jones
7:00AM ET on Monday Apr 29, 2024 by Dow Jones
Apr 25, 2024
Apr 12, 2024
Apr 11, 2024
DJ Aquestive Therapeutics Initiated at Overweight by Piper Sandler, from 6:04AM ET on Thursday Apr 11, 2024 by Dow Jones
6:04AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aquestive Therapeutics Inc | 320.3M | -24.7x | --- |
Sanara Medtech Inc | 279.6M | -62.1x | --- |
Daiichi Sankyo Co Ltd | 62.7B | 49.9x | --- |
Theravance Biopharma Inc | 436.6M | -9.1x | --- |
Dr Reddy's Laboratories Ltd | 12.6B | 19.6x | +32.29% |
Verrica Pharmaceuticals Inc | 303.3M | -4.8x | --- |
Company Information
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Contact Information
- Headquarters
- 30 Technology DrWARREN, NJ, United States 07059-5166
- Phone
- 908-941-1900
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Santo Costa
- President, Chief Executive Officer, Director
- Daniel Barber
- Independent Vice Chairman of the Board
- John Cochran
- Chief Financial Officer, Senior Vice President
- A. Ernest Toth
- Chief Compliance Officer, Senior Vice President, General Counsel and Corporate Secretary
- Lori Braender
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $320.3M |
|---|---|
Revenue (TTM) | $50.6M |
Shares Outstanding | 85.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.92 |
EPS | $-0.14 |
Book Value | $-1.55 |
P/E Ratio | -24.7x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -32.59% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
